ArticleExperimental & molecular medicine2021

REDD1 is a determinant of low-dose metronomic doxorubicin-elicited endothelial cell dysfunction through downregulation of VEGFR-2/3 expression.

Minsik Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.